Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.68 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.68 |
| ▸ | KCNH1 | O95259 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17210677 | 1.00 | BACE1 (0.68) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL15400001 | 1.00 | BACE1 (0.68) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL17210691 | 0.89 | BACE1 (0.79) | BACE1BACE2KCNH1KCNH2 | |
| SCHEMBL17200055 | 0.86 | BACE1 (0.64) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL17210703 | 0.86 | BACE1 (0.64) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL12496806 | 0.86 | BACE1 (0.64) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL12496813 | 0.85 | BACE1 (0.57) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL12496722 | 0.85 | BACE1 (0.57) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL17210695 | 0.85 | BACE1 (0.57) | BACE1BACE2KCNH1KCNH2CYP2D6 | |
| SCHEMBL12496846 | 0.81 | BACE1 (1.00) | BACE1BACE2KCNH1KCNH2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346811-B2 | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-24 | — | — | US | disclosed |
| EP-2681219-B1 | 6,7-DIHYDRO-PYRAZOLO[1,5-A]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2681219-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-A]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica, N.V. (BE) | 2014-01-08 | — | — | EP | disclosed |
| US-20140005200-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-02 | — | — | US | disclosed |
| WO-2012117027-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-A]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005200-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885KCNH1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.